GlassScriptPhysician profile
Shivanand Bomman
NPI 1063641348
$3,035.05
in general payments reported to CMS, 2019-2025
12 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2022: $325 · 2023: $304 · 2024: $1,521 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Travel and Lodging: $742 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.65 |
| Travel and Lodging | $742.32 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $777.23 | 2024 | Hanarostent Esophagus Tts(Ccc) |
| Boston Scientific Corporation | $638.68 | 2022-2025 | Resolution 360 Ultra Clip, General - Therapies, Axios |
| Medtronic, INC. | $341.22 | 2022-2024 | Barrx |
| Janssen Biotech, INC. | $249.00 | 2024 | Stelara, Tremfya |
| Abbvie INC. | $245.41 | 2019-2024 | |
| Enterra Medical, INC. | $171.80 | 2025 | |
| Janssen Scientific Affairs, LLC | $124.39 | 2019 | |
| Ferring Pharmaceuticals INC. | $121.83 | 2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $108.99 | 2019 | |
| Abbott Laboratories | $106.44 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivanand Bomman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.